Krystal Biotech, Inc. (NASDAQ:KRYS) Holdings Lowered by Lord Abbett & CO. LLC

Lord Abbett & CO. LLC cut its stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 24.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 215,628 shares of the company's stock after selling 68,531 shares during the period. Lord Abbett & CO. LLC owned about 0.75% of Krystal Biotech worth $33,780,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the stock. US Bancorp DE boosted its position in shares of Krystal Biotech by 8.7% in the 4th quarter. US Bancorp DE now owns 1,027 shares of the company's stock valued at $161,000 after purchasing an additional 82 shares during the period. Summit Investment Advisors Inc. boosted its holdings in shares of Krystal Biotech by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 2,595 shares of the company's stock valued at $407,000 after acquiring an additional 82 shares during the period. Crossmark Global Holdings Inc. grew its position in shares of Krystal Biotech by 5.5% during the fourth quarter. Crossmark Global Holdings Inc. now owns 2,307 shares of the company's stock worth $362,000 after acquiring an additional 121 shares during the last quarter. Envestnet Asset Management Inc. increased its holdings in shares of Krystal Biotech by 1.1% in the 4th quarter. Envestnet Asset Management Inc. now owns 11,630 shares of the company's stock valued at $1,822,000 after acquiring an additional 121 shares during the period. Finally, Perigon Wealth Management LLC raised its position in Krystal Biotech by 1.5% in the 4th quarter. Perigon Wealth Management LLC now owns 8,289 shares of the company's stock valued at $1,200,000 after purchasing an additional 123 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company's stock.

Krystal Biotech Stock Performance

Shares of KRYS traded down $4.21 during trading hours on Thursday, hitting $165.67. The stock had a trading volume of 111,944 shares, compared to its average volume of 295,093. The company's fifty day simple moving average is $175.64 and its 200 day simple moving average is $171.48. Krystal Biotech, Inc. has a 12-month low of $141.72 and a 12-month high of $219.34. The firm has a market cap of $4.79 billion, a P/E ratio of 55.37 and a beta of 0.75.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, topping analysts' consensus estimates of $1.29 by $0.23. The firm had revenue of $91.10 million during the quarter, compared to analysts' expectations of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The firm's revenue was up 116.4% on a year-over-year basis. During the same period in the prior year, the company earned $0.30 EPS. As a group, sell-side analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on KRYS shares. Chardan Capital upped their target price on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a report on Thursday, February 20th. HC Wainwright raised their target price on shares of Krystal Biotech from $221.00 to $240.00 and gave the stock a "buy" rating in a research note on Monday. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $215.00 price objective on shares of Krystal Biotech in a report on Thursday, February 20th. Citigroup upped their price objective on Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a report on Thursday, February 20th. Finally, Jefferies Financial Group began coverage on shares of Krystal Biotech in a research note on Wednesday, March 5th. They set a "buy" rating and a $245.00 price target on the stock. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $222.71.

Insider Transactions at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the sale, the insider now owns 1,463,711 shares of the company's stock, valued at approximately $260,233,178.69. The trade was a 1.68 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Kathryn Romano sold 750 shares of the company's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the sale, the chief accounting officer now owns 12,604 shares in the company, valued at approximately $2,208,472.88. This trade represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 13.70% of the company's stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).